€59.06
Your prediction
Financial data and news for Halozyme
sharewise wants to provide you with the best news and tools for Halozyme, so we directly link to the best financial data sources.
Financials
News
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme